Confidential

Page 1 of 33

1 **ARTICLE TITLE:**

- 2 Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19:
- 3 The SCORPIO-SR Randomized Clinical Trial
- 4

5 AUTHORS:

- 6 Hiroshi Yotsuyanagi, M.D., Ph.D.,¹ Norio Ohmagari, M.D., Ph.D.,² Yohei Doi, M.D., Ph.D.,^{3,4}
- 7 Masaya Yamato, M.D., Ph.D.,⁵ Nguyen Hoang Bac, M.D., Ph.D.,⁶ Bong Ki Cha, M.D., Ph.D.,⁷
- 8 Takumi Imamura, M.S.,⁸ Takuhiro Sonoyama, M.D., Ph.D.,⁸ Genki Ichihashi, M.Pharm.,⁸ Takao
- 9 Sanaki, Ph.D.,⁹ Yuko Tsuge, M.S.,⁸ Takeki Uehara, Ph.D.,⁸ and Hiroshi Mukae, M.D., Ph.D.¹⁰

10

11 **AFFILIATIONS:**

- ¹The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- ¹³ ²Disease Control and Prevention Center, National Center for Global Health and Medicine,

14 Tokyo, Japan

- ³Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh,
- 16 Pennsylvania, USA
- ⁴Departments of Microbiology and Infectious Diseases, Fujita Health University School of
- 18 Medicine, Toyoake, Japan
- ⁵Infectious Diseases Center, Rinku General Medical Center, Izumisano, Japan
- ⁶Endoscopic Surgery Training Center, University Medical Center, University of Medicine and
- 21 Pharmacy, Ho Chi Minh City, Vietnam
- ⁷Department of Internal Medicine, Chung-Ang Medical Health Care System Hyundae Hospital,
- 23 Gyeonggi-do, Republic of Korea

Confidential

Page 2 of 33

- ⁸Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- ⁹Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
- ¹⁰Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical
- 27 Sciences, Nagasaki, Japan
- 28

29 CORRESPONDING AUTHOR:

- 30 Takeki Uehara
- 31 Drug Development and Regulatory Science Division, Shionogi & Co., Ltd.
- 32 Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan
- 33 Email: <u>takeki.uehara@shionogi.co.jp</u>
- 34 Telephone: +81-6-6209-6907
- 35
- 36 Manuscript word count: 2930 words
- 37

Confidential

Page 3 of 33

38 Key Points

- 39 Question Can ensitelvir, an oral severe acute respiratory syndrome coronavirus 2 3C-like
- 40 protease inhibitor, shorten the duration of symptoms in patients with mild-to-moderate COVID-
- 41 19 irrespective of risk factors for severe disease?
- 42 **Findings** In this phase 3 part of a phase 2/3, double-blind, randomized study SCORPIO-SR, a
- 43 statistically significant difference was observed in the time to resolution of five COVID-19
- 44 symptoms between ensitrelvir 125 mg and placebo in patients randomized in less than 72 hours
- 45 of disease onset. Viral RNA and viral titer demonstrated significant reduction vs placebo.
- 46 **Meaning** Ensittelvir 125 mg treatment shortened time to resolution of key COVID-19
- 47 symptoms.

Confidential

Page 4 of 33

49 Abstract

- 50 **IMPORTANCE** Treatment options for coronavirus disease 2019 (COVID-19) that can be used
- 51 irrespective of risk factors for severe disease are warranted.
- 52 **OBJECTIVE** To assess the efficacy and safety of ensitrelvir in patients with mild-to-moderate

53 COVID-19.

- 54 **DESIGN** The phase 3 part of a phase 2/3, double-blind, randomized, placebo-controlled study
- 55 conducted from February 10 to July 10, 2022.

56 **SETTING** A multicenter study conducted at 92 institutions in Japan, Vietnam, and South Korea.

57 **PARTICIPANTS** Patients (aged 12 to <70 years) with mild-to-moderate COVID-19 within 120

58 hours of positive viral testing.

59 **INTERVENTIONS** Patients were randomized (1:1:1) to receive once-daily ensitedir 125 mg

60 (375 mg on day 1), 250 mg (750 mg on day 1), or placebo for 5 days. Among 1821 randomized

61 patients, 1030 (347, 340, and 343 in the ensitedvir 125-mg, ensitedvir 250-mg, and placebo

62 groups, respectively) were randomized in less than 72 hours of disease onset and assessed as the

63 primary analysis population.

64 MAIN OUTCOMES AND MEASURES The primary end point was the time to resolution of

five COVID-19 symptoms (stuffy or runny nose, sore throat, cough, feeling hot or feverish, and
low energy or tiredness). Other end points included virologic efficacy and safety.

67 **RESULTS** The mean age was 35.7, 35.3, and 34.7 years, and 193 (55.6%), 185 (54.4%), and

68 174 (50.7%) patients were men in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo

69 groups, respectively (intention-to-treat, primary analysis population). A significant difference

70 (P=.04 with a Peto-Prentice generalized Wilcoxon test stratified by vaccination history) was

observed in the primary end point between ensitrelvir 125 mg and placebo in the primary

Confidential

Page 5 of 33

72	analysis population (difference in median, -24.3 hours; 95% confidence interval, -78.7 to 11.7).
73	Viral RNA levels on day 4 and time to negative viral titer demonstrated significant reduction vs
74	placebo. The incidence of adverse events was 44.2%, 53.6%, and 24.8% in the ensittelvir
75	125-mg, ensitrelvir 250-mg, and placebo groups, respectively. No treatment-related serious
76	adverse events were reported.
77	CONCLUSIONS AND RELEVANCE Treatment with ensittelvir 125 mg demonstrated
78	clinical and antiviral efficacy without new safety concerns. Generalizability to non-Asian
79	populations should be confirmed.

80 **TRIAL REGISTRATION** Japan Registry of Clinical Trials identifier: jRCT2031210350.

Confidential

Page 6 of 33

82 Introduction

83	Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, and in November 2021,
84	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant was
85	declared a variant of concern by the World Health Organization. ¹ Patients infected with the
86	omicron variant generally experience mild symptoms. ²⁻⁴ However, despite the worldwide
87	administration of vaccinations, the omicron BA.5* subvariant, which evades vaccine-induced
88	immunity, has become dominant and has resulted in a rapid increase in new COVID-19 cases. ⁵
89	Moreover, emergence of the omicron XBB* and BQ.1* sublineages, which also evade immunity,
90	has been reported worldwide. ⁶
91	Several antiviral drugs against SARS-CoV-2 infection are available worldwide, such as RNA
92	polymerase inhibitors remdesivir ⁷ and molnupiravir, ⁸ and a SARS-CoV-2 3C-like (3CL)
93	protease inhibitor nirmatrelvir combined with pharmacokinetic booster ritonavir.9 However, their
94	clinical trials were conducted in high-risk, unvaccinated patients and at a time when the SARS-
95	CoV-2 Delta or pre-Delta variants were predominant. Therapeutic monoclonal antibodies against
96	SARS-CoV-2 have also been used for COVID-19, but recent in vitro studies suggest that most of
97	them are less efficacious to omicron subvariants than to previous variants. ¹⁰⁻¹² Novel treatment
98	options that can be used irrespective of risk factors for severe disease are thus warranted.
99	Ensitrelvir fumaric acid is an oral SARS-CoV-2 3CL protease inhibitor that originated
100	through collaborative research between Shionogi & Co., Ltd. and Hokkaido University in
101	Japan. ¹³ Ensitrelvir treatment showed antiviral effects against multiple SARS-CoV-2 variants of
102	concern, including omicron subvariants, in <i>in vitro</i> and <i>in vivo</i> studies. ¹³⁻¹⁷ A seamless, phase
103	2/3, double-blind, randomized, placebo-controlled study is currently underway (Japan Registry
104	of Clinical Trials identifier: jRCT2031210350). In the phase 2a and 2b parts, ensitrelvir

Confidential

Page 7 of 33

105	treatment demonstrated decreased viral load vs placebo. ^{18,19} Moreover, improvements in four
106	respiratory symptoms (stuffy or runny nose, sore throat, shortness of breath, and cough) and the
107	composite of the four respiratory symptoms and feverishness were shown in the phase 2b part. ¹⁹
108	The SCORPIO-SR trial is the phase 3 part of the phase 2/3 study and assessed the efficacy and
109	safety of 5-day, once-daily ensitrelvir in patients with mild-to-moderate COVID-19.
110	
111	Methods
112	Study Design
113	The SCORPIO-SR trial was conducted from February 10 to July 10, 2022, across 92 institutions
114	in Japan (65 sites), Vietnam (2 sites), and South Korea (25 sites). The study protocol has been
115	published previously. ²⁰ Patients with mild-to-moderate COVID-19 were randomized (1:1:1) to
116	the ensitrelvir 125 mg, ensitrelvir 250 mg, or placebo group. The patients were followed up until
117	day 28. Considering that the pharmacokinetic/pharmacodynamic analysis of phase 2b part of the
118	current phase 2/3 study did not show a clear difference in antiviral efficacy between the two
119	ensitrelvir dose groups, the 125-mg group was chosen as the efficacy analysis population.
120	Analyses between the ensittelvir 250-mg and placebo groups were performed as a secondary
121	comparison. ²⁰
122	The current phase 2/3 study employed a seamless design to maximize patient recruitment
123	during the SARS-CoV-2 epidemic, and the current phase 3 part was initiated with continuous
124	patient enrollment after the phase 2b part. The phase 3 protocol was amended based on data
125	obtained in the phase 2b part and in view of the changes in clinical features of the epidemic
126	caused by the omicron variant and its subvariants. All protocol amendments, including the
127	changes in the primary endpoint, analysis populations, statistical tests, and sample size

Confidential

Page 8 of 33

128	estimation, were made blinded from the phase 3 data and were finalized based on consultations
129	with infectious disease experts and regulatory authorities. ²⁰
130	This study was conducted in accordance with the principles of the Declaration of Helsinki,
131	Good Clinical Practice guidelines, and other applicable laws and regulations. The study protocol
132	was reviewed and approved by the institutional review boards of all the participating institutions
133	(see the List of Investigators in the Supplement). Written informed consent was obtained from all
134	patients or their legally acceptable representatives.
135	
136	Patients
137	Eligible patients with mild-to-moderate COVID-19 were those aged 12 to <70 years who tested
138	positive for SARS-CoV-2 within 120 hours prior to randomization. Patients should have had a
139	time of \leq 120 hours from the onset of COVID-19 symptoms to randomization and at least one
140	moderate or severe symptom or worsening of an existing moderate or severe symptom among
141	the 12 COVID-19 symptoms defined based on the United States Food and Drug Administration
142	(FDA) guidance ²¹ (eMethods). Key exclusion criteria included an awake oxygen saturation of
143	\leq 93% (room air), supplemental oxygen requirement, anticipated COVID-19 exacerbation within
144	48 hours of randomization, suspected active and systemic infections other than COVID-19
145	requiring treatment, current or chronic history of moderate or severe liver disease, known hepatic
146	or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones), and
147	moderate-to-severe kidney disease (eMethods).
148	

Confidential

Page 9 of 33

149 Randomization, Blinding, and Treatment

150 Patient randomization was performed using an interactive response technology system and 151 stratification by the time from the onset of COVID-19 to randomization (<72 hours vs 152 \geq 72 hours) and SARS-CoV-2 vaccination history (at least one dose of vaccination: yes vs no). 153 All patients and study staff were blinded to the treatment, and emergency unblinding per the 154 investigator's request was allowed in case of occurrence of adverse events to determine the 155 appropriate therapy for the patient. Patients received ensitrelyir (375 mg on day 1 and 125 mg on 156 days 2 through 5 or 750 mg on day 1 and 250 mg on days 2 through 5) or matching placebo 157 tablets, which were identical in appearance and packaging, without dose modification. Treatment 158 was discontinued in case of COVID-19 exacerbation, serious or intolerable adverse events, and 159 pregnancy (eMethods).

160

161 End Points

162 The primary end point was the time to resolution of five COVID-19 symptoms (stuffy or runny 163 nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness) on the basis that 164 they were most commonly observed symptoms in the phase 2b part of the current phase 2/3study, conducted during the omicron BA.1 epidemic.²⁰ Key secondary end points were the 165 166 change from baseline in SARS-CoV-2 viral RNA level on day 4 (key secondary end point 1) and 167 time to first negative SARS-CoV-2 viral titer (key secondary end point 2). The time to resolution 168 of 12 COVID-19 symptoms (above-mentioned five symptoms, shortness of breath, muscle or 169 body aches, headache, chills or shivering, nausea, vomiting, and diarrhea) and 14 COVID-19 170 symptoms (above-mentioned 12 symptoms, anosmia, and dysgeusia) and the SARS-CoV-2 viral 171 RNA and viral titer up to day 21 were assessed as other secondary end points. Resolution of five,

Confidential

Page 10 of 33

172	12, and 14 COVID-19 symptoms was achieved when all the symptoms disappeared, improved,		
173	or maintained after first administration of study intervention and the symptom resolution was		
174	sustained for at least 24 hours in a patient. Each of the 12 COVID-19 symptoms was rated on a		
175	4-point scale (None=0, Mild=1, Moderate=2, or Severe=3), whereas anosmia and dysgeusia were		
176	rated on a 3-point scale (Same as usual=0, Less than usual=1, or No sense of smell/taste=2) by		
177	the patient (eMethods). The safety end point was the incidence of adverse events that emerged		
178	after treatment initiation.		
179			
180	Assessments		
181	The severity of each COVID-19 symptom was recorded in a diary twice daily (morning and		
182	evening) until day 9 and once daily (evening) from days 10 to 21. SARS-CoV-2 viral titer and		
183	viral RNA were quantified using nasopharyngeal swabs collected on days 1 (before drug		
184	administration), 2 to 6 (days 3 and 5 as optional visits), 9, 14, and 21 (or study discontinuation).		
185	Adverse events were coded using the Medical Dictionary for Regulatory Activities, version 24.0		
186	(eMethods).		
187			
188	Statistical Analysis		
189	Considering the main pathophysiology of COVID-19 (viral proliferation for several days		
190	followed by inflammatory reaction by the host immune system starting around 7 days after		
191	onset), antiviral treatment is expected to be most effective when initiated in the early phase of		
192	infection. ²⁰ Based on an epidemiologic analysis in Japan, 62% of patients with COVID-19		
193	hospitalized during the omicron BA.5 epidemic experienced disease progression within 3 days of		
194	the onset. ²² To evaluate the antiviral and clinical efficacy of ensitrelyir in the optimal patient		

Confidential

Page 11 of 33

195	population, the primary analysis population for the primary and key secondary end points was
196	defined as patients randomized in less than 72 hours of disease onset in the intention-to-treat
197	population. ²⁰ As reported previously, ²⁰ assuming a Weibull distribution in the time to resolution
198	of the five COVID-19 symptoms, 230 patients per group were required to compare the survival
199	distributions of the primary end point between the ensittelvir 125-mg and placebo groups using
200	the Peto-Prentice generalized Wilcoxon test with 80% power and a two-sided significance level
201	of .05. Assuming a 10% dropout rate before enrollment, the final sample size for the primary
202	analysis population was set to 260 patients per group (780 patients in total). ²⁰ Of note, patient
203	enrollment was continued as originally planned to include 595 patients randomized within 120
204	hours of disease onset each in the ensitrelvir 125-mg, 250-mg, and placebo groups.
205	The statistical significance vs placebo for the primary end point in the primary analysis
206	population was tested using a Peto-Prentice generalized Wilcoxon test stratified by SARS-CoV-2
207	vaccination history (yes or no). A fixed-sequence hierarchical testing procedure was applied to
208	control for type I errors. The test was performed in the order of primary end point, key secondary
209	end point 1, and key secondary end point 2 in the primary analysis population. The tests were
210	repeated in the same order in patients randomized within 120 hours of disease onset until failure
211	in statistical significance (two-sided significance level of $\geq .05$). ²⁰ All statistical comparisons
212	were performed at a two-sided significance level of .05. No imputation was performed for
213	missing data. All analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC,
214	USA; eMethods).

Confidential

Page 12 of 33

216 **Results**

217 **Patients**

A total of 1821 patients were enrolled; 607, 606, and 608 were randomized to the ensitrelvir

- 219 125-mg, ensitrelvir 250-mg, and placebo groups, respectively (Figure 1). Of the 1821 patients,
- 220 1769 (97.1%) completed the study and 1030 (56.6%) were randomized in less than 72 hours of
- disease onset.
- 222 Patient characteristics were similar across the groups (Table 1 and eTable 1) and were largely
- representative of the expected patient population (eTable 2). In all groups, the mean age was
- approximately 35 years, approximately half of the patients were men, and almost all patients
- were Asian. The majority (>90%) of patients had received ≥ 2 doses of the SARS-CoV-2 vaccine.
- Prior acetaminophen use was recorded for approximately 26% to 36% of the patients. Most
- $(\geq 85\%)$ patients were infected with the omicron BA.1 or BA.2 subvariant. The most common
- 228 COVID-19 symptoms across treatment groups were stuffy or runny nose, sore throat, cough,
- feeling hot or feverish, and low energy or tiredness (Table 1). Approximately 70% of the patients
- 230 were those without risk factors for severe disease (Table 1 and eTable 3).

231

232 **Primary End Point**

A significant difference (P=.04 with a Peto-Prentice generalized Wilcoxon test) was observed

between ensitrelvir 125 mg (median, 167.9 hours; 95% confidence interval [CI], 145.0 to 197.6)

- and placebo (median, 192.2 hours; 95% CI, 174.5 to 238.3) in the time to resolution of the five
- 236 COVID-19 symptoms among patients randomized in less than 72 hours of disease onset, i.e.,
- primary analysis population (difference in median, -24.3 hours; 95% CI, -78.7 to 11.7; Figure
- 238 2A). No significant difference in the time to resolution of the five COVID-19 symptoms was

Confidential

Page 13 of 33

239	observed between ensitrelvir 125 mg and placebo for patients randomized within 120 hours of
240	disease onset (Figure 2B).
241	
242	Key Secondary End Points
243	The least squares mean change from baseline in SARS-CoV-2 viral RNA level (log ₁₀ copies/mL)
244	on day 4 in the primary analysis population was -2.48 (standard error [SE], 0.08) with the
245	ensitelvir 125-mg group, as compared with -1.01 (SE, 0.08) with the placebo group (P<.001)
246	(Table 2). A significant difference (P<.001) was observed in the time to first negative SARS-
247	CoV-2 viral titer in the primary analysis population between ensitrelvir 125 mg (median, 36.2
248	hours; 95% CI, 23.4 to 43.2) and placebo (median, 65.3 hours; 95% CI, 62.0 to 66.8; eFigure
249	1A). Similar results were obtained for patients randomized within 120 hours of disease onset
250	(eFigure 1B).
251	

252 Other Secondary End Points

253 No significant difference was observed in the time to resolution of the 12 COVID-19 symptoms

in the primary analysis population between ensitrelvir 125 mg and placebo. A significant

255 difference (P=.03) was observed in the time to resolution of the 14 COVID-19 symptoms in the

primary analysis population between ensitrelvir 125 mg (median, 187.8 hours; 95% CI, 156.4 to

257 217.0) and placebo (median, 231.8 hours; 95% CI, 192.1 to 265.8; Table 2).

258 No significant difference from placebo was observed with ensitrelvir 125 mg in the time to

- resolution of the 12 and 14 COVID-19 symptoms in patients randomized within 120 hours of
- 260 disease onset (eTable 4). SARS-CoV-2 viral RNA levels and SARS-CoV-2 viral titers in the

Confidential

Page 14 of 33

261	ensitrelvir 125-mg group were significantly lower than those in the placebo group up to day 9	
262	and day 6, respectively, irrespective of time to randomization (eFigure 2A-C and eFigure 3A-C).	
263		
264	Safety	
265	The incidence of adverse events was 44.2%, 53.6%, and 24.8% in the ensittelvir 125-mg,	
266	ensitrelvir 250-mg, and placebo groups, respectively; the incidence of treatment-related adverse	
267	events was 24.5%, 36.2%, and 9.9% in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo	
268	groups, respectively (Table 3). Most of the adverse events were mild, and a majority of	
269	treatment-related adverse events resolved without sequelae.	
270	Serious adverse events were observed in two patients (heavy menstrual bleeding in one	
271	patient in the ensitrelvir 125-mg group on day 14 and acute cholecystitis in one patient in the	
272	placebo group on day 9), both of which were judged as not treatment related. A decrease in high-	
273	density lipoprotein levels was the most frequently reported adverse event (31.1%, 38.6%, and	
274	3.8% in the ensittelvir 125-mg, ensittelvir 250-mg, and placebo groups, respectively) and the	
275	most common treatment-related adverse event (18.4%, 26.2%, and 1.5% in the ensittelvir 125-	
276	mg, ensitrelvir 250-mg, and placebo groups, respectively) in both ensitrelvir groups. Adverse	
277	events leading to treatment discontinuation were recorded in 12 patients. All treatment-related	
278	adverse events leading to treatment discontinuation were deemed to be resolving or resolved	
279	after discontinuation of the study. No adverse events leading to death were reported (Table 3).	
280		
281	Discussion	
282	This phase 3 trial was conducted during the SARS-CoV-2 omicron BA.2 epidemic to assess the	

283 efficacy and safety of 5-day, once-daily, oral ensittelvir for mild-to-moderate COVID-19, using

Confidential

Page 15 of 33

284	the ensitedvir 125-mg group as the efficacy analysis population. ²⁰ More than 90% of the patients
285	had received ≥ 2 doses of the SARS-CoV-2 vaccine, and approximately 70% of the participants
286	did not have risk factors for severe disease. Treatment with ensittelvir 125 mg once daily (375
287	mg on day 1) vs placebo showed a significant difference in the time to resolution of the five
288	typical symptoms of the omicron variant infection in patients randomized in less than 72 hours of
289	disease onset. Moreover, a significant reduction compared with placebo was observed in the two
290	key secondary end points representing antiviral efficacy. In contrast to the results in patients
291	randomized in less than 72 hours of disease onset, no significant difference between ensitrelvir
292	125 mg and placebo was observed in the time to resolution of the five COVID-19 symptoms in
293	patients randomized within 120 hours, suggesting the importance of early treatment initiation.
294	Ensitrelvir was generally well tolerated, and the most commonly observed adverse event, a
295	decrease in high-density lipoprotein level, is consistent with the findings of previous clinical
296	studies of ensitrelvir. ^{18,19,23}
297	Previous clinical trials on oral antivirals for COVID-19 were conducted during the SARS-
298	CoV-2 Delta epidemic. ^{8,9} These trials involved unvaccinated, high-risk adults with COVID-19
299	and demonstrated a reduction in the risk of hospitalization or death as the primary end point. ^{8,9}
300	However, given the administration of vaccinations against COVID-19 and the nature of the
301	infection caused by the omicron variant, these end points could no longer be a viable option.
302	Indeed, published studies report a significant reduction in the risk of death, hospitalization, or
303	severe disease with the omicron vs the Delta infection. ^{3,4,24} Moreover, real-world studies suggest
304	limited effectiveness of these antivirals to high-risk, vaccinated adults or patients infected with
305	the omicron variant in reducing the risk of severe COVID-19. ^{25,26} In the current SCORPIO-SR
306	trial, none of the patients reported mechanical ventilation or death, and only one patient each in

Confidential

Page 16 of 33

307	the ensitrelvir 250-mg and placebo groups required COVID-19-related hospitalization or
308	equivalent recuperation during the study period (data not shown).
309	The symptom-based efficacy end points are suggested by the FDA as an alternative goal in
310	the development of antiviral treatment options for COVID-19 caused by recent SARS-CoV-2
311	variants. ²¹ The phase 2/3 EPIC-SR study employed self-reported, sustained alleviation of all
312	targeted COVID-19 symptoms for four days as a novel primary end point to assess the efficacy
313	of nirmatrelvir with ritonavir. ²⁷ Although a shortened time to sustained alleviation and resolution
314	of COVID-19 signs/symptoms was demonstrated in non-hospitalized adults with COVID-19 at
315	high risk of severe disease (EPIC-HR study), ²⁸ the EPIC-SR study did not show a meaningful
316	difference in the time to sustained symptom alleviation through day 28. ²⁹ The current SCORPIO-
317	SR study met the primary end point and demonstrated clinical efficacy of ensitrelvir in the
318	resolution of COVID-19 symptoms (sustained for at least 24 hours) irrespective of risk factors
319	for severe disease. Sustained resolution or alleviation of self-assessed symptoms can be
320	considered a valid and clinically meaningful efficacy end point for COVID-19 treatment.
321	The major limitation of this study is that it was conducted only in Asian countries, with a
322	limited number of non-Asian patients. The efficacy and safety of ensitrelvir in various patient
323	populations should be further assessed in daily clinical settings.
324	In conclusion, ensittelvir treatment vs placebo demonstrated a reduction in the time to
325	resolution of the five typical COVID-19 symptoms in patients treated in less than 72 hours of
326	disease onset. The results also showed favorable antiviral efficacy of ensitrelvir. No new safety
327	concerns were identified, and ensitrelvir was well tolerated.
328	

Confidential

Page 17 of 33

329 ACKNOWLEDGMENTS

- 330 Author Contributions: Dr Uehara had full access to all the data in the study and takes
- responsibility for the integrity of the data and the accuracy of the data analysis.
- 332 Concept and design: Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura,
- 333 Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, and Hiroshi
- 334 Mukae.
- 335 Acquisition, analysis, or interpretation of data: Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei
- 336 Doi, Masaya Yamato, Nguyen Hoang Bac, Bong Ki Cha, Takumi Imamura, Takuhiro
- 337 Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, and Hiroshi Mukae.
- 338 Drafting of the manuscript: Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao
- 339 Sanaki, Yuko Tsuge, Takeki Uehara.
- 340 Critical revision of the manuscript for important intellectual content: Hiroshi Yotsuyanagi, Norio
- 341 Ohmagari, Yohei Doi, Masaya Yamato, Nguyen Hoang Bac, Bong Ki Cha, Takumi Imamura,
- 342 Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, and Hiroshi

343 Mukae.

344 Statistical analysis: Takumi Imamura.

345 Administrative, technical, or material support: Genki Ichihashi, Takao Sanaki, Yuko Tsuge.

- 346 Supervision: Takeki Uehara, and Hiroshi Mukae.
- 347 **Conflict of Interest Disclosures:** Dr Yotsuyanagi has received consulting fees from Shionogi,
- 348 lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the
- 349 submitted work. He serves as an advisory board member for Shionogi and President of the
- 350 Japanese Society of Infectious Diseases. Drs Ohmagari, Yamato, and Nguyen declare no conflict
- 351 of interest. Dr Doi has received funding relevant to the submitted work from Shionogi and grants

Confidential

Page 18 of 33

352	from Entasis; consulting fees from Gilead Sciences, Moderna, Shionogi, GSK, Meiji Seika,	
353	bioMerieux, and FujiFilm; and lecture fees from Gilead Sciences, Shionogi, MSD, and	
354	bioMerieux outside the submitted work. Dr Bong has received funding relevant to the submitted	
355	work from Ildong Pharmaceutical (partner of Shionogi for the development of ensitrelvir in the	
356	Republic of Korea) and grants from Hyundai Bioscience, Daewoong Pharmaceutical, and Asan	
357	Pharm outside the submitted work. Mr Imamura, Dr Sonoyama, Mr Ichihashi, Mr Sanaki, Ms	
358	Tsuge, and Dr Uehara are full-time employees of Shionogi and may own stocks or stock options	
359	Dr Mukae has received funding relevant to the submitted work from Shionogi, consulting fees	
360	from Shionogi and MSD, and lecture fees from Shionogi, MSD, Gilead Sciences, AstraZeneca,	
361	Pfizer, and GSK outside the submitted work.	
362	Funding/Support: Planning, conduct, and analysis of the study were funded by Shionogi & Co.,	
363	Ltd. and the Organization of the Ministry of Health, Labour and Welfare, Japan.	
364	Role of the Funder/Sponsor: Employees of Shionogi & Co., Ltd. participated in study design;	
365	collection, analysis, and interpretation of data; writing of the report; and decision to submit for	
366	publication.	
367	Meeting presentations: The work reported herein was presented in part at the joint congress of	
368	the 92nd Annual Meeting of the Japanese Association for Infectious Diseases, Western Japan	
369	Branch/the 65th Annual Meeting of the Japanese Association for Infectious Diseases, Central	
370	Japan Branch/the 70th Annual Meeting of the Japanese Society of Chemotherapy, Western Japan	
371	Branch (November 2022).	
372	Additional Contributions: The authors and research team thank all the patients involved in this	
373	study and Masahiro Kinoshita, Manami Yoshida, and Satoshi Kojima (Shionogi & Co., Ltd.) for	

374 preparing technical support documents and an earlier version of the manuscript draft. Support for

Confidential

Page 19 of 33

- data management was provided by EPS Corporation and funded by Shionogi & Co., Ltd.
- 376 Medical writing support was provided by Mami Hirano, M.Sc., of Cactus Life Sciences (part of
- 377 Cactus Communications), and funded by Shionogi & Co., Ltd.

Confidential

Page 20 of 33

379 **REFERENCES**

- 380 1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant
- 381 of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-
- 382 <u>sars-cov-2-variant-of-concern</u>. Accessed June 29, 2023.
- 383 2. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the
- 384 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet*.
- 385 2022;399(10323):437-446.
- 386 3. Auvigne V, Vaux S, Strat YL, et al. Severe hospital events following symptomatic
- 387 infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022:
- a retrospective, population-based, matched cohort study. *EClinicalMedicine*. 2022;48:101455.
- 389 4. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of
- 390 hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta
- 391 (B.1.617.2) variants in England: a cohort study. *Lancet*. 2022;399(10332):1303-1312.
- 392 5. Kopsidas I, Karagiannidou S, Kostaki EG, et al. Global distribution, dispersal patterns,
- and trend of several Omicron subvariants of SARS-CoV-2 across the globe. *Trop Med Infect Dis*.
- 394 2022;7(11):373.
- 395 6. World Health Organization. TAG-VE statement on Omicron sublineages BQ.1 and XBB.
- 396 <u>https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bg.1-and-</u>
- 397 <u>xbb</u>. Accessed June 29, 2023.
- 398 7. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 399 final report. *N Engl J Med.* 2020;383(19):1813-1826.
- 400 8. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral
- 401 treatment of Covid-19 in nonhospitalized patients. *N Engl J Med.* 2022;386(6):509-520.

Confidential

Page 21 of 33

402	9.	Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir fo	or high-risk,
-----	----	--	---------------

- 403 nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-408.
- 404 10. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs
- 405 against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. *N Engl J Med.* 2022;387(5):468-470.
- 406 11. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2
- 407 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22(7):942-
- 408 943.
- 409 12. Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2
- 410 Omicron impacts infectivity and fusogenicity. *Nature*. 2022;603(7902):706-714.
- 411 13. Unoh Y, Uehara S, Nakahara K, et al. Discovery of S-217622, a noncovalent oral SARS-
- 412 CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem.
- 413 2022;65(9):6499-6512.
- 414 14. Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility of SARS-
- 415 CoV-2 Omicron BA.2. Nature. 2022;607(7917):119-127.
- 416 15. Sasaki M, Tabata K, Kishimoto M, et al. S-217622, a SARS-CoV-2 main protease
- 417 inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. *Sci Transl Med.*418 2023;15(679):eabq4064.
- 419 16. Kawashima S, Matsui Y, Adachi T, et al. Ensitrelvir is effective against SARS-CoV-2
- 420 3CL protease mutants circulating globally. *Biochem Biophys Res Commun.* 2023;645:132-136.
- 421 17. Uraki R, Ito M, Kiso M, et al. Antiviral and bivalent vaccine efficacy against an omicron
- 422 XBB.1.5 isolate. *Lancet Infect Dis.* 2023;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1.
- 423 18. Mukae H, Yotsuyanagi H, Ohmagari N, et al. A randomized phase 2/3 study of
- 424 ensittelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-

Confidential

Page 22 of 33

- 425 to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part.
- 426 *Antimicrob Agents Chemother*. 2022;66(10):e0069722.
- 427 19. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients
- 428 with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase
- 429 2/3 study. *Clin Infect Dis.* 2022;76(8):1403-1411. doi: 10.1093/cid/ciac933.
- 430 20. Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2/3 study of S-217622 in participants
- 431 with SARS-CoV-2 infection (phase 3 part). *Medicine (Baltimore)*. 2023;102(8):e33024.
- 432 21. U.S. Food and Drug Administration. Assessing COVID-19-related symptoms in
- 433 outpatient adult and adolescent subjects in clinical trials of drugs and biological products for
- 434 COVID-19 prevention or treatment. <u>https://www.fda.gov/regulatory-information/search-fda-</u>
- 435 guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-
- 436 <u>subjects-clinical-trials-drugs</u>. Accessed June 29, 2023.
- 437 22. Hiroshima Prefectural Health and Welfare Bureau. Findings from the analysis of J-
- 438 SPEED (Surveillance in Post Extreme Emergencies and Disasters, Japan version) data: wave 7
- 439 analysis. <u>https://www.mhlw.go.jp/content/10900000/000975398.pdf</u>. Japanese. Accessed June
- 440 29, 2023.
- 441 23. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety,
- 442 tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-
- 443 CoV-2 3CL protease inhibitor, in healthy adults. *Antimicrob Agents Chemother*.
- 444 2022;66(10):e0063222.
- 445 24. Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta
- 446 (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in
- 447 Bristol, United Kingdom. *Lancet Reg Health Eur.* 2023;25:100556.

Confidential

Page 23 of 33

448 25.	Butler CC	, Hobbs FDR,	Gbinigie	OA, et al.	Molnupiravir	plus u	sual care	versus usual
---------	-----------	--------------	----------	------------	--------------	--------	-----------	--------------

- 449 care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes
- 450 (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. *Lancet*.
- 451 2023;401(10373):281-293.
- 452 26. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of molnupiravir in high-risk
- 453 patients: a propensity score matched analysis. *Clin Infect Dis.* 2023;76(3):453-460.
- 454 27. ClinicalTrials.gov. Evaluation of protease inhibition for COVID-19 in standard-risk
- 455 patients (EPIC-SR). ClinicalTrials.gov identifier: NCT05011513.
- 456 <u>https://clinicaltrials.gov/ct2/show/NCT05011513</u>. Accessed June 29, 2023.
- 457 28. Hammond J, Leister-Tebbe H, Gardner A, et al. 1156. Sustained alleviation and
- 458 resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo. Open
- 459 Forum Infect Dis. 2022;9(Suppl 2):ofac492.994. doi: 10.1093/ofid/ofac492.994.
- 460 29. U.S. Food and Drug Administration. Meeting of the Antimicrobial Drugs Advisory
- 461 Committee March 16, 2023: FDA Briefing Document.
- 462 <u>https://www.fda.gov/media/166197/download</u>. Accessed June 29, 2023.

464 **FIGURES**

465 **Figure 1. Patient Disposition**



- 467 The intention-to-treat population comprised all patients who tested positive for SARS-CoV-2 viral RNA at baseline, as confirmed by
- 468 an RT-PCR test based on the nasopharyngeal swab sample. The modified intention-to-treat population comprised all patients who
- 469 tested positive for SARS-CoV-2 viral RNA and who had detectable SARS-CoV-2 viral titer at baseline.
- 470 RT-PCR, reverse transcription-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Confidential

Page 25 of 33

471 Figure 2. Time to Resolution of Five COVID-19 Symptoms (Intention-to-Treat Population)



473 The analysis was performed for all patients who tested positive for SARS-CoV-2 viral RNA at 474 baseline. Patients randomized in less than 72 hours of disease onset in the ensited vir 125-mg 475 group were defined as the primary analysis population. A Peto-Prentice generalized Wilcoxon 476 test was applied to test the statistical significance vs placebo. The test was stratified by SARS-477 CoV-2 vaccination history (yes or no) for patients randomized in less than 72 hours (panel A) and time from onset to randomization (<72 hours or >72 hours) and SARS-CoV-2 vaccination 478 479 history (yes or no) for patients randomized within 120 hours (panel B). The five COVID-19 480 symptoms were stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy 481 or tiredness. Among patients randomized within 120 hours of disease onset (panel B), the median 482 difference in the time to resolution of the five COVID-19 symptoms between ensittelyir 125 mg 483 and placebo was -10.6 hours (95% confidence interval, -56.9 to 21.3).

Confidential

Page 26 of 33

- 484 COVID-19, coronavirus disease 2019; RNA, ribonucleic acid; SARS-CoV-2, severe acute
- 485 respiratory syndrome coronavirus 2.

Confidential

Page 27 of 33

487 **TABLES**

488 Table 1. Demographic and Clinical Characteristics of the Patients at Baseline (Intention-to-Treat Population)^a

Characteristic	Patients Randomized in Less Than 72 Hours			Patients Randomized Within 120 Hours of			
	of Disease Onset			Disease Onset			
	Ensitrelvir	Ensitrelvir	Placebo	Ensitrelvir	Ensitrelvir	Placebo	
	125 mg	250 mg		125 mg	250 mg		
	(N=347) ^b	(N=340)	(N=343)	(N=603)	(N=595)	(N=600)	
Male sex — no. (%)	193 (55.6)	185 (54.4)	174 (50.7)	318 (52.7)	323 (54.3)	311 (51.8)	
Mean (SD) age — years	35.7 (12.5)	35.3 (12.2)	34.7 (12.2)	35.9 (12.7)	35.9 (12.7)	35.3 (12.6)	
Asian race — no. (%)	345 (99.4)	338 (99.4)	341 (99.4)	601 (99.7)	593 (99.7)	598 (99.7)	
COVID-19 vaccination history — no. (%)							
≥ 1 vaccination	322 (92.8)	313 (92.1)	315 (91.8)	562 (93.2)	551 (92.6)	553 (92.2)	
≥ 2 vaccinations	316 (91.1)	311 (91.5)	310 (90.4)	554 (91.9)	547 (91.9)	545 (90.8)	
\geq 3 vaccinations	183 (52.7)	185 (54.4)	177 (51.6)	284 (47.1)	295 (49.6)	283 (47.2)	
Mean (SD) SARS-CoV-2 viral RNA level — log_{10}	6.98 (1.01)	6 89 (1 01)	6.93 (0.99)	6.83 (1.05)	6 73 (1 08)	677(107)	
copies/mL ^c	0.90 (1.01)	0.09 (1.01)	0.95 (0.99)	0.05 (1.05)	0.75 (1.00)	0.77 (1.07)	
Patients with any risk factors for severe disease —	107 (30.8)	90 (26.5)	89 (25.9)	174 (28.9)	167 (28.1)	152 (25.3)	
no. (%)"							
Prior acetaminophen use — no. (%)	108 (31.1)	90 (26.5)	99 (28.9)	216 (35.8)	191 (32.1)	207 (34.5)	
Mean (SD) oxygen saturation — % ^e	97.3 (1.1)	97.2 (2.0)	97.3 (1.2)	97.4 (1.1)	97.3 (1.6)	97.3 (1.1)	
SARS-CoV-2 variant — no. (%)							
BA.1/21K (omicron)	61 (17.6)	57 (16.8)	54 (15.7)	131 (21.7)	130 (21.8)	115 (19.2)	
BA.2/21L (omicron)	242 (69.7)	232 (68.2)	241 (70.3)	401 (66.5)	376 (63.2)	407 (67.8)	
BA.1.1.529/21M (omicron)	2 (0.6)	0 (0.0)	2 (0.6)	2 (0.3)	1 (0.2)	2 (0.3)	
BA.4/22A (omicron)	1 (0.3)	1 (0.3)	0 (0.0)	1 (0.2)	1 (0.2)	0 (0.0)	
BA.5/22B (omicron)	4 (1.2)	5 (1.5)	5 (1.5)	5 (0.8)	7 (1.2)	8 (1.3)	
BA.2.12.1/22C (omicron)	1 (0.3)	2 (0.6)	0 (0.0)	1 (0.2)	5 (0.8)	2 (0.3)	
Recombinant	30 (8.6)	38 (11.2)	33 (9.6)	52 (8.6)	64 (10.8)	50 (8.3)	
Not tested	2 (0.6)	1 (0.3)	2 (0.6)	2 (0.3)	2 (0.3)	3 (0.5)	
No result	4 (1.2)	4 (1.2)	6 (1.7)	8 (1.3)	9 (1.5)	13 (2.2)	
Patients with COVID-19 symptoms — no. (%) ^f							
Respiratory symptoms				1			

Characteristic	Patients Rand	Patients Randomized Within 120 Hours of				
		Disease Onset				
	Ensitrelvir	Ensitrelvir	Placebo	Ensitrelvir	Ensitrelvir	Placebo
	125 mg	250 mg		125 mg	250 mg	
	(N=347) ^b	(N=340)	(N=343)	(N=603)	(N=595)	(N=600)
Stuffy or runny nose	283 (83.5)	248 (74.3)	247 (75.8)	506 (86.1)	468 (80.6)	464 (80.0)
Sore throat	300 (88.5)	292 (87.4)	286 (87.7)	520 (88.4)	522 (89.7)	512 (88.3)
Shortness of breath	95 (28.0)	90 (26.9)	66 (20.2)	170 (28.9)	158 (27.1)	142 (24.5)
Cough	291 (85.8)	280 (83.8)	287 (88.0)	518 (88.1)	512 (88.0)	518 (89.3)
Systemic symptoms						
Low energy or tiredness	265 (78.2)	248 (74.3)	229 (70.2)	446 (75.9)	407 (69.9)	408 (70.3)
Muscle or body aches	207 (61.1)	209 (62.6)	189 (58.0)	341 (58.0)	333 (57.2)	315 (54.3)
Headache	219 (64.6)	221 (66.2)	213 (65.3)	376 (63.9)	368 (63.2)	367 (63.3)
Chills or shivering	223 (65.8)	172 (51.5)	167 (51.2)	325 (55.3)	276 (47.4)	289 (49.8)
Feeling hot or feverish	247 (72.9)	234 (70.1)	235 (72.1)	378 (64.3)	379 (65.1)	385 (66.4)
Digestive symptoms						
Nausea	49 (14.5)	38 (11.4)	37 (11.3)	81 (13.8)	75 (12.9)	76 (13.1)
Vomiting	18 (5.3)	14 (4.2)	12 (3.7)	33 (5.6)	24 (4.1)	24 (4.1)
Diarrhea	57 (16.8)	49 (14.7)	51 (15.6)	116 (19.7)	104 (17.9)	104 (17.9)
Sensation disturbance						
Anosmia	47 (13.9)	54 (16.2)	38 (11.7)	102 (17.3)	102 (17.5)	93 (16.0)
Dysgeusia	52 (15.3)	50 (15.0)	49 (15.0)	105 (17.9)	91 (15.6)	99 (17.1)

^a Data for all patients who tested positive for SARS-CoV-2 viral RNA at baseline are shown.

- 490 ^b Primary analysis population.
- 491 ^c N=345 for the ensitedvir 125-mg group, N=336 for the ensitedvir 250-mg group, and N=341 for the placebo group in patients randomized in
- 492 less than 72 hours of disease onset. N=600 for the ensittelvir 125-mg group, N=589 for the ensittelvir 250-mg group, and N=597 for the placebo
- 493 group in patients randomized within 120 hours of disease onset.

Confidential

Page 29 of 33

494 ^d Age \geq 65 years, BMI \geq 30 kg/m², cancer, cerebrovascular disease, chronic kidney disease, chronic lung disease, chronic liver disease, cystic

- 495 fibrosis, diabetes mellitus, disabilities, heart conditions, hypertension, dyslipidemia, human immunodeficiency virus, mental health disorders,
- 496 neurologic conditions, primary immunodeficiencies, smoking, solid organ or hematopoietic cell transplantation, tuberculosis, and use of
- 497 corticosteroids or other immunosuppressive medications were considered the risk factors for severe disease.
- 498 ^e N=335 for the ensitedvir 125-mg group, N=327 for the ensitedvir 250-mg group, and N=322 for the placebo group in patients randomized in
- 499 less than 72 hours of disease onset. N=584 for the ensitedvir 125-mg group, N=573 for the ensitedvir 250-mg group, and N=574 for the placebo
- 500 group in patients randomized within 120 hours of disease onset.
- ^f N=339 for the ensitedvir 125-mg group, N=334 for the ensitedvir 250-mg group, and N=326 for the placebo group in patients randomized in
- 502 less than 72 hours of disease onset. N=588 for the ensitedvir 125-mg group, N=582 (581 for stuffy or runny nose) for the ensitedvir 250-mg
- 503 group, and N=580 for the placebo group in patients randomized within 120 hours of disease onset.
- 504 BMI, body mass index; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard 505 deviation.

Confidential

Page 30 of 33

508 Time to Resolution of the 14 COVID-19 Symptoms (Intention-to-Treat Population, Patients Randomized in Less Than 72 Hours of

509	Disease	Onset)
-----	---------	--------

Variable	Ensitrelvir 125 mg (N=347) ^a	Ensitrelvir 250 mg (N=340)	Placebo (N=343)
Change from baseline to day 4 in SARS-CoV-2 viral RNA			
levels ^b			
n	340	333	337
LS mean (SE) — log ₁₀ copies/mL	-2.48 (0.08)	-2.49 (0.08)	-1.01 (0.08)
Difference from placebo, LS mean (SE)	-1.47 (0.08)	-1.48 (0.08)	
95% CI	-1.63 to -1.31	-1.64 to -1.32	
P value	<.001	<.001	
Time to resolution of the 12 COVID-19 symptoms ^c			
n	336	330	321
Median (95% CI) — hours	179.2 (152.1 to 212.1)	184.9 (168.9 to 226.2)	213.2 (185.8 to 253.8)
Difference from placebo, median (95% CI)	-34.0 (-85.9 to 8.3)	-28.3 (-72.8 to 14.7)	
P value ^d	.07	.08	
Time to resolution of the 14 COVID-19 symptoms ^e			
Ν	336	330	321
Median (95% CI) — hours	187.8 (156.4 to 217.0)	190.3 (171.4 to 244.0)	231.8 (192.1 to 265.8)
Difference from placebo, median (95% CI)	-44.1 (-95.3 to 4.5)	-41.5 (-81.2 to 27.3)	
P value ^d	.03	.05	

510 ^a Primary analysis population.

^b Analysis by ANCOVA using baseline SARS-CoV-2 viral RNA and SARS-CoV-2 vaccination history (yes or no) as covariates.

512 ^c Low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough,

513 shortness of breath (difficulty breathing), nausea, vomiting, and diarrhea.

Confidential

Page 31 of 33

- ^d Based on a Peto-Prentice generalized Wilcoxon test stratified by SARS-CoV-2 vaccination history (yes or no).
- 515 ^e Low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough,
- 516 shortness of breath (difficulty breathing), nausea, vomiting, diarrhea, anosmia, and dysgeusia.
- 517 ANCOVA, analysis of covariance; CI, confidence interval; COVID-19, coronavirus disease 2019; LS, least squares; SARS-CoV-2, severe acute
- 518 respiratory syndrome coronavirus 2; SE, standard error.

Confidential

520 **Table 3. Summary of Adverse Events (Safety Analysis Population)**^a

Adverse event category	Ensitrelvir	Ensitrelvir	Placebo	
	(N=604)	(N=599)	(N=605)	
Patients with any adverse event — no. (%)	267 (44.2)	321 (53.6)	150 (24.8)	
Patients with any treatment-related adverse event — no. (%)	148 (24.5)	217 (36.2)	60 (9.9)	
Patients with any serious adverse event — no. (%) ^b	1 (0.2)	0	1 (0.2)	
Patients with adverse events leading to death — no. (%)	0	0	0	
Patients with adverse events leading to treatment discontinuation — no. (%) ^c	4 (0.7)	6 (1.0)	2 (0.3)	
Adverse events occurring in $\geq 2\%$ of patients in either group — no. (%)				
Headache	13 (2.2)	20 (3.3)	14 (2.3)	
Diarrhea	6 (1.0)	9 (1.5)	12 (2.0)	
High-density lipoprotein decreased	188 (31.1)	231 (38.6)	23 (3.8)	
Blood triglycerides increased	49 (8.1)	74 (12.4)	32 (5.3)	
Blood bilirubin increased	36 (6.0)	56 (9.3)	6 (1.0)	
Blood cholesterol decreased	20 (3.3)	28 (4.7)	3 (0.5)	
Bilirubin conjugated increased	15 (2.5)	20 (3.3)	3 (0.5)	
Blood creatine phosphokinase increased	14 (2.3)	8 (1.3)	11 (1.8)	
Blood lactate dehydrogenase increased	6 (1.0)	15 (2.5)	6 (1.0)	
Aspartate aminotransferase increased	4 (0.7)	9 (1.5)	12 (2.0)	
Treatment-related adverse events occurring in $\geq 2\%$ of patients in either group — no.				
(%)				
Headache	4 (0.7)	13 (2.2)	2 (0.3)	
High-density lipoprotein decreased	111 (18.4)	157 (26.2)	9 (1.5)	
Blood triglycerides increased	16 (2.6)	37 (6.2)	17 (2.8)	
Blood bilirubin increased	17 (2.8)	35 (5.8)	3 (0.5)	
Blood cholesterol decreased	8 (1.3)	12 (2.0)	1 (0.2)	

^a Data for all patients who received at least one ensittelvir or placebo dose are shown.

^b Both serious adverse events were judged as not treatment related and recovered with appropriate intervention.

Confidential

Page 33 of 33

⁵²³ ^c Among the adverse events leading to treatment discontinuation, mild eczema and mild vomiting in one patient each in the ensittelvir 125-mg group, mild rash and moderate rash in one patient each in the ensittelvir 250-mg group, and moderate hypoesthesia and mild muscular weakness in one patient in the placebo group were judged as treatment related by the investigator. All treatment-related adverse events leading to treatment discontinuation.